3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
2
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Carcinoma, Hepatocellular
11
Stomach Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Squamous Cell Carcinoma of Head and Neck
9
Lung Neoplasms
8
Colorectal Neoplasms
8
Rectal Neoplasms
5
Advanced Solid Tumor
5
Head and Neck Neoplasms
4
Triple Negative Breast Neoplasms
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm, Residual
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Solid Tumour
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of External Auditory Canal
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Simpson-Golabi-Behmel syndrome
1
Sarcoma
1
Renal Pelvic Carcinoma
1
Interventions
Cyclophosphamide
13
pembrolizumab
8
Brentuximab Vedotin
8
fludarabine
7
Nivolumab
7
Whole-Body Irradiation
6
Specimen Handling
6
Mycophenolic Acid
6
Gemcitabine
6
Etoposide
6
Doxorubicin
6
Dacarbazine
6
fludarabine phosphate
5
Vinblastine
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Dexamethasone
5
Stem Cell Transplantation
4
Cytarabine
4
Vinorelbine
3
Tacrolimus
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
Carmustine
3
Blood Specimen Collection
3
thymoglobulin
2
polatuzumab vedotin
2
pegylated granulocyte colony-stimulating factor
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hodgkin Disease
×
tislelizumab
×
Clear all
NCT05977673
2025-12-08
FIL_Tisle-HL
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled